Extravasation de paclitaxel (Taxol®)

Raymond, Éric; Cartier, S.; Canuel, C; Louvet, C.; Demuynck, B.; Debray, Marcel; Varette, C.; Baux, S; Mimoun, Maurice; Gramont, Aimery de; Krulik, M

doi:10.1016/0248-8663(96)80679-5

Cited by 13 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only mild skin and soft tissue lesions following paclitaxel extravasation which subsided within 2 weeks were observed in four cases by Du Bois et al [15]. Stein et al [16] and Raymond et al [17] each reported on one case with reversible cellulitis and sharply demarked erythema, local heat, and blisters following extravasation of paclitaxel. Berghmans and Klastersky [18] saw erythema, cellulitis, and small vesicles with peeling of the skin after 3 weeks and painless induration persisting for at least 3 months in one case of paclitaxel extravasation.…”

Section: Discussionmentioning

confidence: 99%

Extravasation of Paclitaxel (TAXOL<sup>®</sup>) – Clinical Course

Riedel¹,

Serke²,

Schönfeld³

et al. 1999

Oncol Res Treat

View full text Add to dashboard Cite

Background: Clinical information on paclitaxel extravasation is scarce. A clinical course following paclitaxel extravasation is reported with an overview of the literature. Case Report: A 74-year-old male patient with small-cell lung cancer mistakenly received approximately 100 ml of a subcutaneous infusion containing approximately 60 mg of paclitaxel. A severe cutaneous reaction was seen within 30 min, followed by a systemic reaction with dizziness on day 2, fever and hypotension on day 5, and leuko- and thrombocytopenia on day 10. Sclerosis, hyperpigmentation, and neuropathic pain developed in the forearm and slowly subsided within 6–8 months. Conclusion: Paclitaxel extravasation may cause severe cutaneous and rarely even systemic reversible reactions. Paclitaxel must be considered a vesicant.

show abstract

Section: Discussionmentioning

confidence: 99%

Extravasation of Paclitaxel (TAXOL<sup>®</sup>) – Clinical Course

Riedel¹,

Serke²,

Schönfeld³

et al. 1999

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…In fact, a number of authors reported histopathologic findings described as either coagulative, ischemic, or fat necrosis [1,9,16,19,23,31]. In fact, a number of authors reported histopathologic findings described as either coagulative, ischemic, or fat necrosis [1,9,16,19,23,31].…”

Section: Discussionmentioning

confidence: 99%

“…A French group [31] reported on a 71-year-old ovarian cancer patient who, during her sixth cycle of paclitaxel treatment through a Port-a-Cath, complained of burning, redness, and breast tension in the right breast. The area was edematous and hot; after a few days vesicles appeared which opened and bled.…”

Section: Case Reports Of Paclitaxel Extravasationmentioning

confidence: 99%

A review of clinical experience with paclitaxel extravasations

Stanford¹,

Hardwicke²

2003

Support Care Cancer

View full text Add to dashboard Cite

Paclitaxel is a novel antineoplastic with a wide spectrum of activity in various malignant tumors. Extravasation of chemotherapy drugs is a widely feared adverse event in oncology patients. A Medline search between 1966 and October 2002 was conducted to identify case reports related to paclitaxel extravasation, as well as a bibliography screening of identified papers. The goal of this work is to summarize the available reports of paclitaxel extravasation and assess its vesicant potential. Additionally, management strategies for extravasation events due to paclitaxel are assessed.

show abstract

“…Conservative management usually results in complete recovery, and the taxanes are normally considered to be predominantly irritant and only mildly vesicant. In animal models, paclitaxel led to skin ulceration and necrosis, proving its borderline vesicant character [9,[41][42][43]. A treatment with intradermal hyaluronidase diluted in saline was effective in preventing paclitaxel-induced ulceration.…”

Section: Non-anthracyclinesmentioning

confidence: 97%

Extravasation of Chemotherapy

Langer

2010

Curr Oncol Rep

View full text Add to dashboard Cite

Extravasation of chemotherapy is a feared complication of anticancer therapy. The accidental leakage of cytostatic agents into the perivascular tissues may have devastating short-term and long-term consequences for patients. In recent years, the increased focus on chemotherapy extravasation has led to the development of international guidelines that have proven useful tools in daily clinical practice. Moreover, the tissue destruction in one of the most dreaded types of extravasation (ie, anthracycline extravasation) now can effectively be prevented with a specific antidote, dexrazoxane.

show abstract

Extravasation de paclitaxel (Taxol®)

Cited by 13 publications

References 1 publication

Extravasation of Paclitaxel (TAXOL<sup>®</sup>) – Clinical Course

Extravasation of Paclitaxel (TAXOL<sup>®</sup>) – Clinical Course

A review of clinical experience with paclitaxel extravasations

Extravasation of Chemotherapy

Contact Info

Product

Resources

About